Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 523 results for physical activity

  1. What factors encourage under-represented groups to participate in and complete an exercise referral scheme? What factors prevent these groups from participating? Under-represented groups include: people from black and minority ethnic groups, people with disabilities and those from lower socioeconomic groups.

    health by helping people to be more physically active. Changes in physical activity levels should, therefore, be the primary outcome...

    Research recommendation
    Published
    9 June 2015

  2. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What...

    Research recommendation
    Published
    9 June 2015

  3. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

    NICE guideline
    Last updated
    2 June 2017
    View recommendations

    Sections for NG65

  4. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

    NICE guideline
    Published
    20 June 2018
    View recommendations

    Sections for NG97

  5. How effective and cost effective are different types of exercise referral scheme? Compare the relative effects of different models in controlled studies. Include health-related quality of life as an outcome. Compare exercise referral schemes that vary by: - setting – for example, home-based, gym-based, community-based or outdoors - intensity and duration – for example, a 12-week scheme involving 1 session a week, or a 6-week scheme involving 4 1-hour sessions per week - the techniques used, for example, some use additional 'supportive' techniques such as 'motivational interviewing' and education sessions - the target group, for example, people who are overweight and obese, people with raised blood pressure or cholesterol levels or those experiencing mild depression, anxiety or stress; or by age, gender, race or socioeconomic status - other scheme characteristics including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it is commissioned and delivered by an NHS, non-NHS or community-based organisation.

    including: design, content and delivery; referral mechanisms; choice of activity; cost and qualifications of instructors; and whether it...

    Research recommendation
    Published
    9 June 2015

  6. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

    NICE guideline
    Published
    14 September 2016
    View recommendations

    Sections for NG54

  7. Autism (QS51)

    This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    21 January 2014
    View quality statements

    Sections for QS51

  8. Bedwetting in under 19s (CG111)

    This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.

    Clinical guideline
    Published
    27 October 2010
    View recommendations

    Sections for CG111

  9. Suspected neurological conditions: recognition and referral (QS198)

    This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    8 January 2021
    View quality statements

    Sections for QS198

  10. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA676

  11. Swallowable gastric balloon capsule for weight loss (HTG561)

    Evidence-based recommendations on swallowable gastric balloon capsules for weight loss in adults. This involves swallowing a capsule containing a balloon that is then filled with liquid to inflate it in the stomach.

    HealthTech guidance
    Published
    18 November 2020
    View recommendations

    Sections for HTG561

  12. Coexisting severe mental illness and substance misuse (QS188)

    This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    20 August 2019
    View quality statements

    Sections for QS188

  13. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

    NICE guideline
    Last updated
    24 June 2019
    View recommendations

    Sections for NG123

  14. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

    NICE guideline
    Published
    27 February 2015
    View recommendations

    Sections for NG4

  15. Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA918)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    11 October 2023
    View recommendations

    Sections for TA918